Related Experiment Videos
Cross-talk between bone morphogenic proteins and estrogen receptor signaling
Tetsuya Yamamoto1, Fahri Saatcioglu, Tadashi Matsuda
1Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku Kita 12 Nishi 6, Sapporo 060-0812, Japan.
Endocrinology
|June 20, 2002
Summary
Estrogen (E2) inhibits bone morphogenetic protein (BMP) signaling by directly interacting with Smad proteins, a novel cross-talk mechanism between BMP and estrogen receptor (ER) pathways.
Area of Science:
- Molecular Biology
- Cell Signaling
- Endocrinology
Background:
- Bone morphogenetic proteins (BMPs) are crucial for cell differentiation and tissue remodeling.
- Estrogens regulate diverse biological processes, including tissue development and maintenance.
- Estrogens were previously known to suppress BMP function via gene expression repression.
Purpose of the Study:
- To elucidate a novel mechanism by which estrogens inhibit BMP signaling.
- To investigate the direct interaction between estrogen signaling and BMP pathways.
Main Methods:
- Utilized breast cancer cells and mesangial cells.
- Administered 17beta-estradiol (E2) to assess BMP-2-induced Smad activation and gene expression.
- Used tamoxifen, an estrogen receptor (ER) antagonist, to reverse E2-mediated effects.
- Provided evidence of direct physical interactions between Smad proteins and ER.
Main Results:
- 17beta-estradiol (E2) suppressed BMP-2-induced Smad activity and gene expression in tested cell types.
- Tamoxifen reversed the inhibitory effects of E2 on Smad activation.
- Demonstrated direct physical interactions between Smad proteins and the estrogen receptor (ER).
Conclusions:
- Estrogen receptor (ER) directly inhibits Smad activity through physical interaction.
- This represents a novel mechanism for cross-talk between BMP and ER signaling pathways.
- Estrogen's inhibitory effect on BMP function is mediated by direct protein-protein interaction with Smads.